Abstract
Tuberculosis (TB) kills more youth and adults than any other infectious disease in the world today. The emergence of new strains of Mycobacterium tuberculosis resistant to some or all current antituberculosis drugs is a serious and crescent problem. The resistance is often a corollary to HIV infection and drug-resistant TB is more difficult and more expensive to treat, besides to be more likely fatal. Thus, it is still necessary to search for new antimycobacterial agents. The identification of novel targets need the identification of biochemical pathways specific to mycobacteria and related organisms. Many unique metabolic processes occur during the biosynthesis of mycobacterial cell wall components. In this report, we examine one of these attractive targets for the rational design of new antituberculosis agents - the mycolic acids.
Current Drug Targets
Title: An Approach for the Rational Design of New Antituberculosis Agents
Volume: 2 Issue: 4
Author(s): K. F. M. Pasqualoto and E. I. Ferreira
Affiliation:
Abstract: Tuberculosis (TB) kills more youth and adults than any other infectious disease in the world today. The emergence of new strains of Mycobacterium tuberculosis resistant to some or all current antituberculosis drugs is a serious and crescent problem. The resistance is often a corollary to HIV infection and drug-resistant TB is more difficult and more expensive to treat, besides to be more likely fatal. Thus, it is still necessary to search for new antimycobacterial agents. The identification of novel targets need the identification of biochemical pathways specific to mycobacteria and related organisms. Many unique metabolic processes occur during the biosynthesis of mycobacterial cell wall components. In this report, we examine one of these attractive targets for the rational design of new antituberculosis agents - the mycolic acids.
Export Options
About this article
Cite this article as:
M. Pasqualoto F. K. and Ferreira I. E., An Approach for the Rational Design of New Antituberculosis Agents, Current Drug Targets 2001; 2 (4) . https://dx.doi.org/10.2174/1389450013348227
DOI https://dx.doi.org/10.2174/1389450013348227 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Desferrioxamine as Immunomodulatory Agent During Microorganism Infection
Current Pharmaceutical Design Anti-Tuberculosis
Current Bioactive Compounds Fluoroquinolones: An Important Class of Antibiotics Against Tuberculosis
Current Medicinal Chemistry Gauging Reactive Metabolites in Drug-Induced Toxicity
Current Medicinal Chemistry Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review
Reviews on Recent Clinical Trials Brevifoliol and its Analogs: A New Class of Anti-tubercular Agents
Current Topics in Medicinal Chemistry Stem Cells in MDR-TB and XDR - TB
Current Respiratory Medicine Reviews HIV-1 Matrix Protein p17 and its Receptors
Current Drug Targets Emerging Therapies in Relapsing-Remitting Multiple Sclerosis
Reviews on Recent Clinical Trials Patent Selections
Recent Patents on DNA & Gene Sequences Role of Lipopolysaccharides in Potential Applications of Nanocarrier Systems
Current Pharmaceutical Design Human Tuberculosis II. M. tuberculosis Mechanisms of Genetic and Phenotypic Resistance to Anti-Tuberculosis Drugs
Current Medicinal Chemistry Pleuroparenchymal Fibroelastosis: Its Pathological Characteristics
Current Respiratory Medicine Reviews Update on the Management of Spondyloarthritis in Asian Countries
Current Rheumatology Reviews Prediction of Cytochrome 450 Mediated Drug-Drug Interactions by Three-Dimensional Cultured Hepatocytes
Mini-Reviews in Medicinal Chemistry Antimicrobial and Biofilm Inhibiting Diketopiperazines
Current Medicinal Chemistry Docking and PLS Studies on a Set of Thiophenes RNA Polymerase Inhibitors Against Staphylococcus aureus
Current Topics in Medicinal Chemistry Epidemiology and Pathophysiology of Chronic Cough
Current Respiratory Medicine Reviews Bacteriophage and Peptidoglycan Degrading Enzymes with Antimicrobial Applications
Recent Patents on Biotechnology Enhanced Production of Cholesterol Oxidase from Bacillus sp. COX-T<sub>3</sub> in a Biphasic System
Current Biotechnology